Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
EGFR
cfDNA
non-small cell lung cancer (NSCLC)
plasma
tyrosine kinase inhibitor (TKI)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
ppublish
Résumé
Analysis of circulating free DNA (cfDNA) by the real-time PCR cobas A prospective cohort of 173 locally advanced or metastatic NSCLC TKI-naïve patients analyzed by the cobas The test showed high diagnostic accuracy when compared to the gold standard of biopsy tumor tissue testing. The SQI value showed a moderate reproducibility (r The study indicates that cfDNA analysis in plasma for
Sections du résumé
BACKGROUND
BACKGROUND
Analysis of circulating free DNA (cfDNA) by the real-time PCR cobas
METHODS
METHODS
A prospective cohort of 173 locally advanced or metastatic NSCLC TKI-naïve patients analyzed by the cobas
RESULTS
RESULTS
The test showed high diagnostic accuracy when compared to the gold standard of biopsy tumor tissue testing. The SQI value showed a moderate reproducibility (r
CONCLUSIONS
CONCLUSIONS
The study indicates that cfDNA analysis in plasma for
Identifiants
pubmed: 33841957
doi: 10.21037/jtd-20-3142
pii: jtd-13-03-1658
pmc: PMC8024825
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1658-1670Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-3142). Dr. NR reports personal fees from MSD, personal fees from AMGEM, personal fees from TAKEDA, personal fees from ASTRAZENECA, personal fees from NOVARTIS, personal fees from ABBVIE, personal fees from PFIZER, personal fees from GUARDANT HEALTH, personal fees from BOERINGHER INGELHEIM, personal fees from ROCHE, personal fees from BMS, outside the submitted work. Dr. NV reports personal fees from ROCHE, personal fees from PFIZER, personal fees from LILLY and other financial relationships with BMS, BOERINGHER INGELHEIM, LILLY and ASTRAZENECA, outside the submitted work. The other authors have no conflicts of interest to declare.
Références
J Transl Med. 2018 Nov 6;16(1):300
pubmed: 30400802
Tumour Biol. 2016 Oct;37(10):13687-13694
pubmed: 27473086
Clin Transl Oncol. 2018 Oct;20(10):1261-1267
pubmed: 29623586
Biomol Detect Quantif. 2019 Mar 18;17:100087
pubmed: 30923679
Clin Chim Acta. 2015 Oct 23;450:243-53
pubmed: 26341895
Br J Cancer. 2015 Jul 28;113(3):476-83
pubmed: 26125447
Br J Cancer. 2020 Jul;123(1):81-91
pubmed: 32376889
Biomed Res Int. 2018 May 8;2018:7392419
pubmed: 29854785
Nat Rev Clin Oncol. 2014 Aug;11(8):473-81
pubmed: 24981256
Oncotarget. 2017 Feb 14;8(7):12501-12516
pubmed: 27980215
Clin Chim Acta. 2018 Apr;479:14-19
pubmed: 29309771
J Mol Diagn. 2018 Jul;20(4):483-494
pubmed: 29704571
Biochem Biophys Rep. 2018 Jun 30;15:45-51
pubmed: 29984326
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Oncotarget. 2017 Jan 24;8(4):5861-5873
pubmed: 28052016
Cancer Genet. 2019 Jun;235-236:65-71
pubmed: 31105051
PLoS One. 2017 Aug 22;12(8):e0183331
pubmed: 28829813
Ann Oncol. 2019 Apr 1;30(4):597-603
pubmed: 30891595
Oncotarget. 2017 Nov 16;9(1):488-494
pubmed: 29416630
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
Oncotarget. 2018 Apr 6;9(26):18529-18539
pubmed: 29719623
Adv Lab Med. 2020 Apr 27;1(3):20200009
pubmed: 37361495
J Thorac Oncol. 2016 Oct;11(10):1682-9
pubmed: 27468938
Cancers (Basel). 2019 Mar 30;11(4):
pubmed: 30935089
Eur Respir J. 2015 Dec;46(6):1773-80
pubmed: 26493785
Cancer Genet. 2019 Nov;239:75-84
pubmed: 31639530
Oncotarget. 2017 Aug 9;8(43):75712-75726
pubmed: 29088904
J Cell Mol Med. 2013 Jan;17(1):205-11
pubmed: 23305095
Sci Rep. 2020 Jul 28;10(1):12564
pubmed: 32724107
Clin Cancer Res. 2016 May 15;22(10):2386-95
pubmed: 26747242
J Thorac Oncol. 2015 Oct;10(10):1437-43
pubmed: 26295376
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
Clin Transl Med. 2019 Apr 18;8(1):14
pubmed: 31001798
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2800-12
pubmed: 24294366
J Clin Oncol. 2016 Oct 1;34(28):3375-82
pubmed: 27354477
Dis Markers. 2019 Jan 23;2019:7954921
pubmed: 30809319
J Mol Diagn. 2009 May;11(3):182-5
pubmed: 19324991
J Clin Pathol. 2013 Feb;66(2):79-89
pubmed: 23172555
Pathol Oncol Res. 2020 Apr;26(2):845-851
pubmed: 30847713
Lung Cancer. 2015 Dec;90(3):509-15
pubmed: 26494259
Adv Lab Med. 2020 Jul 27;1(3):20200055
pubmed: 37361499
J Thorac Oncol. 2013 Jul;8(7):823-59
pubmed: 23552377
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
pubmed: 15741570
Ann Transl Med. 2017 Sep;5(18):379
pubmed: 29057239
Oncol Lett. 2018 Jan;15(1):795-802
pubmed: 29399148
Br J Cancer. 2018 Nov;119(10):1252-1258
pubmed: 30397287
JCO Precis Oncol. 2019 Dec;3:1-9
pubmed: 35100738
Oncotarget. 2019 Jun 04;10(38):3654-3666
pubmed: 31217900